Oncolytics Biotech (TSE:ONC) Stock Passes Above Two Hundred Day Moving Average of $1.63

Oncolytics Biotech Inc. (TSE:ONCGet Rating)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$1.63 and traded as high as C$1.76. Oncolytics Biotech shares last traded at C$1.74, with a volume of 3,474 shares traded.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada set a C$6.00 price objective on shares of Oncolytics Biotech and gave the stock an “outperform” rating in a research report on Monday, August 22nd.

Oncolytics Biotech Trading Down 1.1 %

The company has a quick ratio of 13.30, a current ratio of 15.49 and a debt-to-equity ratio of 1.70. The stock has a market capitalization of C$100.69 million and a PE ratio of -3.61. The business’s 50-day moving average is C$1.65 and its two-hundred day moving average is C$1.63.

Oncolytics Biotech Company Profile

(Get Rating)

Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.

Read More

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.